Yuan Q, Xie Y, Peng Z, et al. - This study was intended to assess whether urinary magnesium predicts risk of cardiovascular disease in chronic kidney disease stage 1–4 patients. A prospective population-based cohort study was conducted to assess 3,179 individuals aged 18–74 years with chronic Kidney Disease (CKD) stage 1–4 in the Chinese Cohort Study of Chronic Kidney Disease study. Researchers examined data applying Spearman rank-order correlation coefficients for all comparisons. They also conducted a time-to-event analysis of the data applying the Kaplan–Meier survival model, Cox proportional hazard model and competing risk Fine and Gray subdistribution hazard model. When modelling end-stage renal disease (ESRD), cardiovascular disease (CVD) and death, 24 h UMg was associated with risk of CVD (HR, 1.612 (95% CI, 1.056–2.460)) During a median follow-up of 4.19 years (interquartile range, 3.43–5.09 years), while there was no significant relationship with ESRD and death endpoints. It was shown that 24 h UMg risk variants display a modest association with CVD in CKD stage 1–4 patients.